CJC-1295 + Ipamorelin blend

CJC-1295 + Ipamorelin is a two-peptide growth-hormone-secretagogue blend combining CJC-1295 and Ipamorelin in one vial, sold strictly for research use only. Unlike the tissue-repair blends, it works on the pituitary — and because "CJC-1295" can mean two different molecules, the per-component lab data above is what confirms which one, and how much, is in the vial.

What is the CJC-1295 + Ipamorelin blend?

CJC-1295 + Ipamorelin is a two-peptide blend that pairs a growth-hormone-releasing hormone (GHRH) analog with a selective growth-hormone secretagogue, most commonly 5 mg of each for 10 mg total, sold for research use only. CJC-1295 is a synthetic GHRH analog that raises baseline growth-hormone output; Ipamorelin is a selective ghrelin-receptor (GHS-R) agonist that triggers a clean GH pulse. Most blends use the without-DAC form of CJC-1295 (also called Modified GRF 1-29), which has a roughly 30-minute half-life, rather than the with-DAC form that persists 6–8 days.

The two components, and what each contributes:

This pairing belongs to the growth-hormone-secretagogue family rather than the tissue-repair blends, and is discussed alongside comparators in Ipamorelin vs sermorelin vs tesamorelin.

Why are CJC-1295 and Ipamorelin combined?

CJC-1295 and Ipamorelin are combined because they raise growth hormone through two complementary mechanisms that amplify each other. CJC-1295, as a GHRH analog, increases the amount of GH available for release and raises trough levels; Ipamorelin, as a selective ghrelin-receptor agonist, triggers a distinct GH pulse — and unlike older secretagogues, it does so with minimal effect on cortisol or prolactin. Used together, the GHRH analog and the secretagogue produce a larger, more physiological pulsatile GH release than either alone, which is the rationale behind the stack. The mechanism is covered in the Ipamorelin science guide and the CJC-1295 without-DAC science guide.

What does the research show for CJC-1295 and Ipamorelin?

No controlled clinical trial of the CJC-1295 + Ipamorelin combination has been published as of July 2026, but the individual components have more human data than most research peptides. CJC-1295 was tested in healthy adults in Teichman et al. 2006 (J Clin Endocrinol Metab), where single injections produced 2–10-fold increases in plasma GH sustained for six or more days and 1.5–3-fold IGF-1 elevations lasting 9–11 days (evidence level: human Phase 1/pharmacodynamic). Ipamorelin was characterised as the first selective GH secretagogue — stimulating GH release without significantly raising cortisol or prolactin — primarily in preclinical and early human work (evidence level: preclinical and early clinical). What has not been established in controlled trials is whether either compound, or the combination, produces the body-composition or recovery outcomes marketed for it. The blend inherits its rationale from these single-compound findings, not from trial data on the stack.

CJC-1295 with DAC vs without DAC — which is in the blend?

The blend almost always uses CJC-1295 without DAC, the short-acting form, not the long-acting with-DAC version — and confirming which one you have is part of verifying the vial. The two are genuinely different molecules: without-DAC CJC-1295 (Modified GRF 1-29) has a roughly 30-minute half-life and is dosed to mimic a natural GH pulse alongside Ipamorelin, while with-DAC CJC-1295 carries a Drug Affinity Complex that extends its half-life to 6–8 days. Pairing Ipamorelin with the short-acting form is deliberate: both act on a similar short timescale, producing a pulse rather than a sustained elevation.

For the two CJC-1295 forms compared head-to-head, see CJC-1295 vs CJC-1295 with DAC; for the with-DAC science, see CJC-1295 with DAC; and for how Ipamorelin sits among GH secretagogues, GHRP-2 vs GHRP-6 vs Ipamorelin.

Why verify a CJC-1295 + Ipamorelin vial?

A CJC-1295 + Ipamorelin vial is worth verifying because two things can be wrong that a single number won't reveal: which form of CJC-1295 is present, and whether each peptide is at label strength. A certificate reports one whole-vial HPLC purity — how clean the material is — but that can read above 99% while a component is underdosed, so the verifiable signals are per-component identity (mass spectrometry confirming both peptides, and distinguishing with-DAC from without-DAC CJC-1295 by molecular weight) and net content (tested milligrams versus label, for each). Because the two CJC-1295 forms behave very differently, identity confirmation matters even more here than in a repair blend. Peptigrity's independent lab-test database publishes both dimensions; learn to read them in how to read peptide lab test results.

How does Peptigrity verify a CJC-1295 + Ipamorelin vial?

Peptigrity verifies a CJC-1295 + Ipamorelin vial through four independent measurements from an accredited third-party lab: LC-MS identity confirming both peptides are present and distinguishing which CJC-1295 form it is by molecular weight, HPLC-UV purity for the whole vial, per-component net content (tested versus labelled milligrams for each), and endotoxin testing. The identity step carries extra weight here because with-DAC and without-DAC CJC-1295 differ by roughly 280 Da and produce very different pharmacokinetics. Peptigrity purchases vials anonymously at standard pricing and publishes the unedited certificate; the methodology and shop trust-score weighting are documented in how we calculate trust scores. The broader process is in the how to test peptides hub and the testing labs directory. For sourcing each component, see where to buy CJC-1295 and where to buy Ipamorelin.

How do you dose the CJC-1295 + Ipamorelin blend?

In a fixed CJC-1295 + Ipamorelin vial you set the dose of one peptide and the other follows the ratio, since the two are typically present in equal amounts. A common research-planning approach reconstitutes a 10 mg vial (5 mg of each) and draws a single dose, often timed before sleep to align with the body's natural overnight GH pulse. The dedicated CJC-1295 + Ipamorelin calculator converts the per-component amounts into a reconstitution and draw, and the CJC-1295 + Ipamorelin stack dosing guide covers timing and format. No clinical dosing protocol exists for the combination; every figure is community-derived from single-compound research, not a validated regimen.

What is the regulatory status of CJC-1295 and Ipamorelin?

Neither CJC-1295 nor Ipamorelin is approved by the FDA or any other regulator for human use as of July 2026, and the blend is sold strictly as a research-use-only compound. In April 2026 the FDA removed CJC-1295 from its 503A Category 2 bulk-substances list following withdrawal of its nomination, but did not move it to Category 1 — leaving both growth-hormone secretagogues in a regulatory gray zone, with no FDA-approved product and no USP monograph. Both CJC-1295 and Ipamorelin are prohibited by the World Anti-Doping Agency under class S2 (peptide hormones, growth factors, and related substances), meaning the stack is banned in competitive sport. Buyers are responsible for confirming local import rules for research chemicals in their jurisdiction.